**Review**

**Novel Biomarkers for the Diagnosis of Urinary Tract Infection—A Systematic Review**

Neha Nanda and Manisha Juthani-Mehta

Department of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA.
Email: neha.nanda@yale.edu

**Abstract:** Urinary tract infections (UTIs) are associated with significant morbidity. We rely on clinical presentation, urinalysis, and urine culture to diagnose UTI. To differentiate between lower UTI and pyelonephritis, we depend on the clinical presentation. In the extremes of age and in immunocompromised individuals, clinical presentation is often atypical posing a challenge to diagnosis. In the elderly, the high prevalence of asymptomatic bacteriuria is another confounder. We conducted a search of publications to find novel biomarkers to diagnose UTI and to ascertain its severity. We searched PUBMED, MEDLINE and SCOPUS databases for studies pertaining to novel biomarkers and UTI. Two reviewers independently evaluated the methodology of the studies using the STARD (Standards for Reporting of Diagnostic Accuracy) criteria. We have identified procalcitonin as a biomarker to differentiate lower UTI from pyelonephritis in the pediatric age group. Elevated serum procalcitonin levels can result in early and aggressive treatment at the time of presentation. Interleukin 6 has also shown some promise in differentiating between lower UTI and pyelonephritis but needs further validation. Lastly, given the paucity of data in certain subgroups like diabetics, kidney transplant recipients, and individuals with spinal cord injury, further studies should be conducted in these populations to improve diagnostic criteria that will inform clinical management decisions.

**Keywords:** urinary tract infection, novel biomarkers

---

This article is available from http://www.la-press.com.

© the authors, licensee Libertas Academica Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://www.creativecommons.org/licenses/by/2.0) which permits unrestricted use, distribution and reproduction provided the original work is properly cited.
Introduction

Urinary tract infection (UTI) is a common bacterial infection in all age groups. The prevalence in infants is 6.5% and 3.3% in girls and boys, respectively. Among infants, approximately 60% of febrile UTIs will result in renal scarring which increases the risk of secondary hypertension. In adults age 65 years or older, it is the second most common cause of infectious disease related hospitalizations. UTI accounts for up to 30% of all infectious complications in kidney transplant recipients. UTI appearing in the first three months of kidney transplantation is associated with pyelonephritis, bacteremia, and allograft dysfunction. In individuals with spinal cord injuries (SCI), UTI is the second most common cause of death. Catheter associated UTI is the most common nosocomial infection in US hospitals and nursing homes. Other populations predisposed to UTI include diabetics and individuals with polycystic kidney disease. Despite significant morbidity associated with UTI, making a diagnosis and establishing the severity of infection in the urinary tract remains a challenge.

Establishing the severity and extent of infection (i.e. lower UTI vs. pyelonephritis) is important to determine further management. The duration of treatment in uncomplicated UTI (i.e. involving lower urinary tract) is generally shorter compared to complicated UTI (i.e. involving renal parenchyma). If there is renal parenchymal involvement, the antibiotic of choice would be one that has excellent penetration in the renal parenchyma. Untreated pyelonephritis in young children can lead to secondary hypertension because of renal scarring. Acute pyelonephritis at the extremes of age and in immunocompromised individuals can result in sepsis, renal abscess, hydronephrosis and rarely xanthogranulomatous pyelonephritis. The typical clinical presentation of lower UTI includes frequency, urgency, and dysuria. Classic symptoms of pyelonephritis include fever, flank pain along with lower UTI symptoms. Often the absence of fever indicates lower UTI and not upper UTI. Multiple studies have shown that clinical characteristics alone are inadequate to localize the site of infection in the urinary tract.

Biggi et al showed that high fever was not a reliable sign to discriminate pyelonephritis from lower UTI. Maximum temperature in the lower UTI group and pyelonephritis group was 39 ± 0.7 °C and 39.2 ± 0.6 °C, respectively (P = 0.91). The sensitivity and specificity of temperature more than 39.1 °C, to diagnose pyelonephritis, was 64% and 38% respectively. In another study by Farnsworth et al of the 29 individuals, 12 (41%) had parenchymal involvement but were afebrile.

With the aforementioned limitations of clinical evaluation, biological markers (biomarkers) may have the potential to diagnose UTI and determine the severity of infection. A biomarker is defined as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.” To differentiate between lower UTI and pyelonephritis, biomarkers like erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and white blood count (WBC) have been studied in children. The sensitivity of ESR to determine renal parenchymal damage varies with the cut off. A retrospective study, using a cut off of >10 mm/h for ESR yielded a sensitivity and specificity of 100% and 8%. A prospective study using a cut off >68 mm/hr for ESR yielded a sensitivity and specificity of 48% and 50% respectively. For CRP, to diagnose pyelonephritis, the sensitivity was 64% and specificity was 68%. White blood count of more than 14,601 cells/mm³ has a sensitivity and specificity of 56% and 58% to diagnose pyelonephritis. Given the variable results of these biomarkers, it is challenging to use these biomarkers alone to detect renal parenchymal damage and therefore we rely on radiological studies. Further, to make a diagnosis of lower UTI, we use urinalysis and urine culture results. Given the high incidence of asymptomatic bacteriuria (ASB) and no evidence to treat ASB in the general population, differentiating between UTI and ASB is imperative. Leukocyte esterase and nitrite are biomarkers measured in urinalysis for diagnosing UTI. The absence of either or both of these biomarkers makes either condition extremely unlikely. However, the presence of either or both of these biomarkers does not assist in differentiating ASB from UTI. Therefore, novel biomarkers that can assist in the diagnosis and determination of severity of disease for UTI need to be identified.

Methods

Studies eligible for review

Studies evaluating serum and urine biomarkers for the diagnosis of UTI in humans were included.
Prospective, retrospective, cohort, case control studies, or randomized controlled trials were included.

Finding relevant studies
PUBMED, MEDLINE and SCOPUS databases were searched for “urinary tract infection”, “biological marker” and “diagnosis” and then limited to studies published in the English language from 1997 through 2008 in human subjects. After selecting and reviewing relevant articles, we identified potential novel biomarkers. We identified novel biomarkers based on the number and quality of studies conducted for a given biomarker. Then we searched all databases (PUBMED, MEDLINE and SCOPUS) using “urinary tract infection” with each potential novel biomarker, with the same limits noted above.

Quality assessment
The STARD (Standards for Reporting of Diagnostic Accuracy) criteria were utilized to assess the validity of the studies. The studies were graded based on a checklist that included nine STARD criteria relevant to this review (see Table 1). Studies were divided into three categories based on scores. A score of 8–9 indicates good quality, 6–7 indicates fair quality, and 5 or less is categorized as poor quality. Two reviewers independently graded the studies. Disagreements were discussed until a consensus was reached.

Results
Six hundred seventy three citations were identified with the initial search, of which 21 articles were selected. Articles that were excluded were not relevant to our study question, i.e. did not discuss UTI and novel biomarkers. We identified procalcitonin (PCT), interleukin 6 (IL-6) and interleukin 8 (IL-8) as potential novel biomarkers for diagnosing urinary tract infection and assessing the severity of infection. With the second search (“urinary tract infection” with “PCT” or “IL-6” or “IL-8”), six additional articles were retrieved. A full text analysis of 27 articles resulted in the inclusion of 26 studies (see Fig. 1). Two studies were deemed of good quality and fourteen studies were of fair quality. The remaining studies were of

| Validity criterion      | Description                                                                 | Scoring                      |
|-------------------------|-----------------------------------------------------------------------------|------------------------------|
| Participant recruitment | Was recruitment based on presenting symptoms or not?                        | Presenting symptoms (1)      |
|                         |                                                                             | No presenting symptoms (0)   |
| Participant sampling    | Was the study population a convenience sample or consecutive series of participants defined by the inclusion and exclusion criteria, setting and locations where data were collected? | Consecutive series (1)       |
|                         |                                                                             | Convenience sample (0)       |
| Data collection         | Was data collection planned before the index test and reference standard test (i.e. prospectively or retrospectively)? | Prospectively (1)            |
|                         |                                                                             | Retrospectively (0)          |
| Reference standard      | Was the rationale for reference standard stated?                            | Stated (1)                   |
|                         |                                                                             | Not stated (0)               |
| Materials and methods   | Were technical specifications of materials and methods including how and when measurements were taken stated? | Stated (1)                   |
|                         |                                                                             | Not stated (0)               |
| Index test              | Were the definition of and rationale for the units, cut offs of the results of the index tests and reference standards stated? | Stated (1)                   |
|                         |                                                                             | Not stated (0)               |
| Blinding                | Readers of index test and reference standard blinded?                       | Blinded (1)                  |
|                         |                                                                             | Not blinded or not stated (0) |
| Completion              | Was the number of participants that did not undergo index tests (#test vs. sample size) stated? | Stated (1)                   |
|                         |                                                                             | Not stated (0)               |
| Time Interval           | Was the time interval from index test to reference standard stated?         | Stated (1)                   |
|                         |                                                                             | Not stated (0)               |
poor quality. One study was not scored because of inadequate information (see Tables 2 and 3).

All studies deemed as good and fair quality are discussed in this review.

**Procalcitonin (PCT)**

Procalcitonin (PCT) is a propeptide of calcitonin. It was first described by Assicot et al as a marker of bacterial invasion.\(^ {17}\) In healthy humans, it is produced in the C-cells of the thyroid gland, and during a severe bacterial infection, it is produced by the monocyte-macrophage system. In humans, after the 3rd day of life, a normal plasma PCT level is less than 0.5 µg/l.

Eight articles studying serum PCT and urinary tract infection were identified. One study was of good quality, five were fair and the remaining were of poor quality.\(^ {18}\) Most of these studies were conducted in the pediatric age group with an aim to differentiate

---

*Abbreviations: UTI, urinary tract infection PCT, procalcitonin ILs, interleukins.*

---
between acute pyelonephritis and lower UTI. The reference standard for parenchymal damage in all of these studies was 99mTc-dimercaptosuccinic acid (DMSA) scintigraphy.

Benador et al conducted a prospective study in 80 children who were 1 month to 16 years of age. At presentation, PCT, C reactive protein (CRP) and white blood cell count (WBC) were compared in children with pyelonephritis and lower UTI.\textsuperscript{18} There were statistically significant differences between the two groups for all three parameters, but only PCT had a good correlation with increasing severity of scintigraphic changes noted on DMSA. In the pyelonephritis group, PCT was 5.37 µg/L (95% confidence interval [CI] 1.57 to 9.17) and 0.38 µg/L (95% CI 0 to 0.76) in the lower UTI

| Reference       | Biomarker                        | Serum/urine            | Score |
|-----------------|----------------------------------|------------------------|-------|
| Procalcitonin (PCT) |                                   |                        |       |
| Pecile et al\textsuperscript{22} | PCT                              | Serum                  | 8     |
| Guven et al\textsuperscript{23} | PCT                              | Serum                  | 7     |
| Benador et al\textsuperscript{18} | PCT                              | Serum                  | 7     |
| *Gurgoze et al\textsuperscript{19} | PCT, IL-1β, IL-6 and TNF-α       | Serum                  | 7     |
| Grevaix et al\textsuperscript{26} | PCT                              | Serum                  | 6     |
| Smolkin et al\textsuperscript{21} | PCT                              | Serum                  | 6     |
| Prat et al\textsuperscript{39} | PCT                              | Serum                  | 5     |
| Tuerlinckx et al\textsuperscript{40} | PCT                              | Serum                  | 4     |
| Interleukins (ILs)   |                                   |                        |       |
| Sheu et al\textsuperscript{25} | IL-6 and IL8                      | Serum and Urine        | 7     |
| Olszyna et al\textsuperscript{24} | IL-8                             | Urine                  | 7     |
| Sheu et al\textsuperscript{29} | IL-1β                             | Urine                  | 6     |
| Krzemein et al\textsuperscript{27} | IL-6 and IL-8                     | Urine                  | 6     |
| Otto et al\textsuperscript{28} | Chemokines                        | Serum and Urine        | 6     |
| Jantausch et al\textsuperscript{25} | IL-6 and IL-8                     | Urine                  | 6     |
| Rolilides et al\textsuperscript{41} | IL-6                             | Urine                  | 5     |
| Zaki et al\textsuperscript{42} | IL-8                             | Urine                  | 5     |
| Oregioni et al\textsuperscript{43} | IL-8                             | Urine                  | 3     |
| Rao et al\textsuperscript{44} | IL-8                             | Urine                  | 3     |
| Miscellaneous       |                                   |                        |       |
| Fretzayas et al\textsuperscript{30} | E-α1-Pi                          | Urine and plasma       | 8     |
| Arao et al\textsuperscript{31} | Lactoferrin                       | Urine                  | 6     |
| Deo at al\textsuperscript{32} | Secretory IgA                     | Urine                  | 6     |
| Bakokas et al\textsuperscript{33} | E-α1-Pi                          | Urine and plasma       | 5     |
| Smith et al\textsuperscript{35} | NBT reduction                     | Urine                  | 5     |
| Everaert et al\textsuperscript{34} | α-1 microglobulin/serum prostatic antigen | Urine-α-1 microglobulin and Serum prostatic antigen | 4 |
| Steinhoff et al\textsuperscript{36} | Myeloperoxidase, CRP and α2-macroglobulin | Urine-myeloperoxidase and α2 macroglobulin; serum CRP | 3 |
| Determann et al\textsuperscript{45} | Soluble triggering receptor expressed on myeloid cells-1 | Serum | NA |

*Study evaluating PCT, IL-1β, IL-6 and TNF-α.
| Validity criterion                  | Explanation                                                                 | Scoring                                      | Procalcitonin (PCT)\(^a\) | Interleukins (ILs)\(^b\) | Miscellaneous\(^c\) |
|------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------|-----------------------------|---------------------------|---------------------|
| Participant recruitment            | Was recruitment based on presenting symptoms or not?                       | Presenting symptoms (1)                      | All studies recruited based on presenting symptoms (1), except one.\(^{40}\) | All studies recruited based on presenting symptoms except three.\(^{41,43,44}\) | All studies recruited based on presenting symptoms except two.\(^{35,36}\) |
|                                   |                                                                             | No presenting symptoms (0)                   |                             |                           |                     |
| Participant sampling               | Was the study population a convenience sample or consecutive series of      | Consecutive series (1)                       | All studies used consecutive series | All studies used consecutive series except three.\(^{42-44}\) | All studies used consecutive series except three.\(^{31,35,36}\) |
|                                   | participants defined by the inclusion and exclusion criteria, setting and   | Convenience sample (0)                      |                             |                           |                     |
|                                   | locations where data were collected?                                        |                                              |                             |                           |                     |
| Data collection                    | Was data collection planned before the index test and reference standard    | Prospectively (1)                           | Planned and performed       | Planned and performed     | Planned and        |
|                                   | test (i.e. prospectively or retrospectively)?                               | Retrospectively (0)                         | prospectively in all studies| prospectively in all      | performed           |
|                                   |                                                                             |                                              |                             | except two studies.       | studies in all      |
|                                   |                                                                             |                                              |                             |                           | except one study.   |
| Reference standard                 | Was the rationale for reference standard stated?                           | Stated (1)                                  | Rationale for reference     | Rationale for reference   | Rationale for       |
|                                   |                                                                             | Not stated (0)                               | standard mentioned in the   | standard mentioned in the | reference standard   |
|                                   |                                                                             |                                              | only five studies.\(^{18,19,21-23}\) | only except one study.\(^{41}\) | mentioned in all     |
|                                   |                                                                             |                                              |                             |                           | except one study.\(^{33}\) |
| Materials and Methods              | Were technical specifications of materials and methods including how and    | Stated (1)                                  | Stated in all studies       | Stated in all studies     | Stated in all       |
|                                   | when measurements were taken?                                              | Not stated (0)                               |                             |                           | studies except two  |
|                                   |                                                                             |                                              |                             |                           | studies.\(^{31,34,35}\) |
|                                  |                                                                             |                                              |                             |                           |                     |
| Index test                         | Were the definition of and rationale for the units, cut offs of the        | Stated (1)                                  | Not stated in any of the    | Not stated in any of the  | Stated in three     |
|                                   | results of the index tests and reference standards stated?                 | Not stated (0)                               | studies                      | studies                   | studies only.\(^{31,32,35}\) |
| Blinding                           | Readers of index test and reference standard blinded?                       | Blinded (1)                                 | Stated that the readers of  | Not stated in any of the  | Stated that readers  |
|                                   |                                                                             | Not blinded or not stated (0)                | the index test               | studies                   | of the index and     |
|                                   |                                                                             |                                              | and reference test          |                          | reference test were  |
|                                   |                                                                             |                                              | were blinded in four studies.\(^{18,20,22,23}\) |                          | blinded in only two   |
| Completion                         | Was the number of participants that did not undergo index tests (#test vs.| Stated (1)                                  | Stated in three studies.\(^{19,22,23}\) | Stated in all except four | Stated in only three    |
|                                   | sample size) stated?                                                        | Not stated (0)                               |                             | studies.\(^{27,29,43}\) | studies.\(^{30,33,35}\) |
| Time Interval                      | Was the time interval from index test to reference standard stated?         | Stated (1)                                  | Stated in all except one    | Stated in all except three| Stated in all except |
|                                   |                                                                             | Not stated (0)                               | study.\(^{23}\)              | studies.\(^{25,42,44}\) | four studies.\(^{32-34,36}\) |

\(^{a}\)Total of 8 studies identified.
\(^{b}\)Total of 11 studies identified.
\(^{c}\)Total of 8 studies identified.
group. Gürgöze et al conducted a prospective study in 76 children with UTI. There were 34 subjects in the acute pyelonephritis group and 42 in lower UTI group. Median PCT level obtained at presentation was significantly higher in the acute pyelonephritis group, i.e. 1.68 ng/ml (range 0.14 to 5.4) vs. 0.1 ng/ml (range 0.1 to 3.2), P < 0.001. Using a cut-off of 0.5 ng/ml, to diagnose pyelonephritis, the sensitivity and specificity of PCT was 94% and 58% respectively. In a smaller group of children (n = 54), Grevaix et al also confirmed a higher level of PCT in the setting of parenchymal damage compared with lower UTI.

In another prospective study of 64 children, Smolkin et al demonstrated that in acute pyelonephritis, the median PCT was 3.41 µg/L (range 0.36 to 12.4) while in lower UTI, the median PCT was 0.13 µg/L (range 0.02 to 2.15), P < 0.0001. In this study, using a cut-off of 0.5 µg/L, PCT had a sensitivity of 94.1% and specificity of 89.7% for detecting pyelonephritis.

Pecile et al prospectively showed that PCT can serve as a marker of severity of acute pyelonephritis in children. The study included 100 children. Mean PCT increased proportionally with the extent of renal involvement (P < 0.0001). PCT levels at admission were lower in patients with completely reversible lesions (mean 3.25 ng/ml, 95% CI 0 to 10.25) versus those with partially reversible lesions or renal scarring (mean 7.48 ng/ml, 95% CI 0 to 24.28), P = 0.04. A cut-off value of 0.8 ng/ml yielded the best diagnostic accuracy with a sensitivity of 83.3% and specificity of 93.7% to diagnose acute pyelonephritis.

Lastly, Guven et al conducted a prospective study with 33 children and were unable to show a significant correlation between parenchymal damage and PCT, CRP and WBC. Subjects were enrolled based on presenting symptoms and diagnosis of acute pyelonephritis was confirmed with DMSA. In summary, PCT is a good marker to predict renal parenchymal damage in the pediatric age group. It has not been studied in other populations to make a diagnosis of UTI or to identify renal parenchymal damage as a result of infection.

**Interleukins (ILs)**

Interleukins are a family of cytokines that play a key role in the regulation of the immune system. We identified 11 articles studying interleukins in the setting of UTI. Seven articles were graded as fair quality and the rest were poor quality. Interleukin 6 (IL-6) and interleukin 8 (IL-8) have been studied in adults to diagnose UTI and in children to differentiate between pyelonephritis and lower UTI.

Urinary IL-8 has been suggested as a biomarker for UTI in catheterized postoperative patients. In a study by Olsyzna et al, urinary IL-8 and IL-6 were measured prospectively. A diagnosis of UTI was made if the patient had at least one clinical symptom of UTI plus greater than 100,000 CFU/ml on urine culture. One hundred and sixty five patients were initially enrolled and 10 were diagnosed with UTI. Twenty patients, matched for duration of catheterization, served as controls. Urinary IL-8 increased on the day the urine culture became positive in the UTI group, while in the control group it was unchanged. Urinary IL-8 increased from approximately 10 to 125 ng/mmol of creatinine in the UTI group and remained constant at approximately 10 ng/mmol of creatinine in the control group. Urinary IL-6 increased in both the case and control groups.

Jantausch et al prospectively studied urinary IL-6 and IL-8 as markers for UTI in children age 0–12 years. Bacterial UTI was defined as a urine culture with greater than 100,000 CFU/ml in a midstream clean catch specimen or greater than 10,000 CFU/ml in a catheterized specimen. The control group included febrile subjects with infections other than UTI. At the time of admission, the median urinary IL-6 concentration for subjects (n = 37) with proven bacterial UTI was 397 pg/ml (range 0 to 65,790 pg/ml) vs. 0 pg/ml (range 0 to 473.8 pg/ml) for controls (n = 37), P < 0.0001. The median urinary IL-8 concentration for the bacterial UTI group (n = 32) was 5809 pg/ml (range 0 to 347,368 pg/ml) vs. 0 (range 0 to 2231 pg/ml) for the controls (n = 32), P < 0.0001.

Sheu et al compared the utility of serum and urine levels of IL-6 and IL-8 for diagnosing acute pyelonephritis. Seventy eight children aged 1–121 months with a first episode of febrile UTI were included. Twelve healthy children who were matched for age and sex served as controls. All patients with suspected UTI received antibiotics at the time of presentation. Serum and urine IL-6 and IL-8 were collected at presentation. Acute pyelonephritis was confirmed with DMSA. The initial value of both interleukins in serum and urine was significantly higher in patients with acute pyelonephritis (n = 42) compared with lower UTI (n = 36) and healthy controls (n = 12). Serum IL-6 was 67.5 ± 75.4 pg/ml (mean ± standard deviation [SD]) in the pyelonephritis
Serum IL-8 concentration was higher in patients with clinical signs of acute pyelonephritis than in the group with lower UTI symptoms. In the pyelonephritis group, median IL-8 was 1.45 ng/ml (range 0.31 to 7.70) and 0.88 ng/ml (range 0.20 to 4.10) in the lower UTI group but the difference was not significant.

IL-1 is another immunoregulatory cytokine. IL-1β is a subtype of IL-1, found in free form in biological fluids like serum, urine, and synovial fluid. IL-1β has also been studied to differentiate between acute pyelonephritis and lower UTI. In addition to investigating PCT and IL-6, Gürgoze et al determined that serum IL-1β had a sensitivity of 97% and a specificity of 59% for detecting pyelonephritis. A cut-off of 6.9 pg/ml was used to distinguish between pyelonephritis and lower UTI. In the pyelonephritis group, median IL-1β was 32.3 pg/ml (range 1.63 to 70.2) and in the lower UTI group, median IL-1β was 1.64 pg/ml (range 0 to 14.55), P < 0.001. Similarly, urinary IL-1β proved to be a helpful marker in another study comparing patients with acute pyelonephritis (n = 41), lower UTI (n = 34), and febrile controls (n = 20, patients with upper respiratory infection, lower respiratory infection, otitis media, and gastroenteritis). There was a significant difference in IL-1β levels at presentation in all three groups; acute pyelonephritis (172 ± 263.3 pg/ml, mean ± SD), lower UTI (20.4 ± 41.2 pg/ml) and febrile controls (4.6 ± 14 pg/ml).

IL-6 and IL-8 have been studied in several settings including diagnosing UTI in adults in the post-operative setting, in diagnosing bacterial UTI in children, and in diagnosing pyelonephritis in children. Serum IL-6 is a possible novel biomarker to diagnose acute pyelonephritis in children but further studies are warranted. Currently, there are discrepant results when using urinary IL-6, serum and urinary IL-8 to diagnose acute pyelonephritis in children and adults.

**Miscellaneous**

Besides PCT and IL, other novel biomarkers have been studied to diagnose UTI. We identified eight articles discussing these biomarkers. Among these, the article regarding polymorphonuclear elastase was rated as a good quality article. Studies discussing urinary lactoferrin and urinary secretory IgA were fair quality based on our scores.

Elastase is a protease stored in neutrophils. It is present in plasma and urine in a formed complex
Biomarkers for urinary tract infection

We have conducted an extensive literature review for novel biomarkers that would help in the diagnosis of UTI and assist in establishing its severity. We have identified procalcitonin (PCT) as a potential biomarker that can help in differentiating between lower UTI and pyelonephritis in the pediatric age group.

**Lower UTI vs. pyelonephritis**

Procalcitonin (PCT), interleukin 6 (IL-6), and interleukin 8 (IL-8) have been studied to diagnose acute pyelonephritis at an early stage. PCT has shown promising results in this setting. The sensitivity and specificity of PCT ranges from 58% to 94.1% and 36.4% to 93.6%, respectively. These numbers are based on the studies graded as good and fair quality in this review. Most of these studies enrolled children who were less than 1 year to 12 years of age. PCT has not been studied in other populations in the setting of UTI. Serum IL-6 has shown some promise in differentiating between acute pyelonephritis and lower UTI in two studies. Both these studies were done in children less than 12 years of age. Interleukin 8 has been studied with negative results in a similar setting.

Approximately 60% of children with febrile UTI develop acute pyelonephritis and 30% of those develop renal scars. 99mTc-dimercaptosuccinic acid (DMSA) scintigraphy is the gold standard used to diagnose renal scars. This is often performed six months after the acute presentation. DMSA is not available in all settings and involves radiation exposure. PCT is a potential biomarker that can be used in settings where DMSA may not be readily available. This can predict renal parenchymal damage at the time of presentation in the pediatric age group. A recent prospective study comparing PCT, ESR and CRP showed superior results with PCT to assess renal parenchymal damage. Furthermore, a high PCT (>0.5 ng/ml) has shown to be associated with vesicoureteral reflux in children.

It is a non-invasive test that can help physicians make decisions regarding management and further assessment. Given the wide ranges in sensitivity and specificity, further study of PCT to distinguish lower UTI from pyelonephritis is warranted.

**Diagnosis of lower UTI**

We identified three studies using urine interleukin 8 (IL-8) and lactoferrin (LF) to diagnose UTI. All three biomarkers such as soluble triggering receptor expressed on myeloid cells-1, urinary myeloperoxidase, α-2 macroglobulin, and the ratio of urinary α-1 microglobulin and serum prostatic antigen have also been studied to diagnose UTI, differentiate between upper and lower UTI and UTI from renal graft rejection.

Since most of studies done in this group were of poor quality, it is challenging to advocate the use of these markers in clinical practice.
Special populations
We were unable to identify studies targeted to populations like individuals with spinal cord injury, diabetics, individuals with polycystic kidney disease, and the elderly (adults 65 years or older). One study specially focusing on kidney transplant recipients was identified. This study aimed at differentiating between UTI and allograft rejection based on a panel of biomarkers. At this time, no recommendations can be made for diagnosing UTI or ascertaining the severity of infection in these populations.

Proposed research agenda
To further our ability to diagnose the manifestations of bacterial infections in the urinary tract, the following areas may serve as topics for future research.

- PCT is a promising biomarker in the pediatric age group for diagnosing acute pyelonephritis. This should be studied in other populations as well.
- Serum IL-6 needs to be studied in a larger population to establish its potential as a biomarker to diagnose UTI.
- Target studies to other subgroups including individuals with spinal cord injury, diabetics, individuals with polycystic kidney disease, and the elderly (adults 65 years or older) such that they may have direct applicability to patient care.
- Continued search for additional novel biomarkers, that are specific to the urinary system, to diagnose UTI.

As studies in this field progress, it is conceivable that one may be able to develop a weighted model that uses the information on the available biomarkers. With this information one can compute a cumulative score to differentiate between ASB and UTI and identify renal parenchymal damage earlier on.

Acknowledgements
We would like to thank Dr. Chirag Parikh for his guidance with this manuscript. Dr. Juthani-Mehta is supported by NIH/NIA Claude D. Pepper Older Americans Independence Center (P30-AG21342); NIA RO3-AG028057; NIA K23-AG028691; Atlantic Philanthropies; IDSA/NFID; John A. Hartford Foundation; Association of Specialty Professors; CTSA Grant Number UL1 RR024139 from the National Center for Research Resources (NCRR).

Disclosures
The authors report no conflicts of interest.

References
1. Bressan S, Andreola B, Zucchetta P, et al. Procalcitonin as a predictor of renal scarring in infants and young children. Pediatric nephrology. 2009; 24(6):1199–204.
2. Hoberman A, Charron M, Hickey RW, Baskin M, Kearney DH, Wald ER. Imaging studies after a first febrile urinary tract infection in young children. The New England Journal of Medicine. 2003;348(3):195–202.
3. Jacobson SH, Ekloff O, Eriksson CG, Lins LE, Tidgren B, Winberg J. Development of hypertension and uremia after pyelonephritis in childhood: 27 year follow up. BMJ (Clinical research ed.). 1989;299(6701):703–6.
4. Curns AT, Holman RC, Sejvar JJ, Owings MF, Schonberger LB. Infectious disease hospitalizations among older adults in the United States from 1990 through 2002. Archives of Internal Medicine. 2005;165(21):2514–20.
5. Charfeddine K, Zaghdan S, Kharrat M, Kamoun K, Jarraya F, Hachicha J. Infectious complications in kidney transplant recipients: a single-center experience. Transplantation proceedings. 2005;37(6):2823–5.
6. Frankel HL, Coll JR, Charlifue SW, et al. Long-term survival in spinal cord injury: a fifty year investigation. Spinal Cord. 1998;36(4):266–74.
7. Tambyah PA, Maki DG. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. Archives of Internal Medicine. 2000;160(5):678–82.
8. Lichtenberger P, Hooton TM. Complicated urinary tract infections. Current Infectious Disease Reports. 2008;10(6):499–504.
9. Tenner SM, Yadven MW, Kimmel PL. Acute pyelonephritis. Preventing complications through prompt diagnosis and proper therapy. Postgraduate Medicine. 1992;91(2):261–8.
10. Sobel JD and Kaye D. Urinary tract infections. In: GL Mandell JB, Raphael Dolin, ed Principles and Practice of Infectious Diseases. 2005:875–901.
11. Biggi A, Dardanelli L, Pomero G, et al. Acute renal cortical scintigraphy in children with a first urinary tract infection. Pediatric nephrology (Berlin, Germany). 2001;16(9):733–8.
12. Farnsworth RH, Rossleigh MA, Leighton DM, Bass SJ, Rosenberg AR. The detection of reflux nephropathy in infants by 99mtechnetium dimercaptosuccinic acid studies. *The Journal of Urology*. 1991; 145(3):542–6.

13. Garin EH, Olavarria F, Azarya C, Brousseau M, Barrera C, Young L. Diagnostic significance of clinical and laboratory findings to localize site of urinary infection. Pediatric Nephrology (Berlin, Germany). 2007;22(7):1002–6.

14. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clinical Pharmacology and Therapeutics*. 2001;69(3):89–95.

15. Juthani-Mehta M, Tinetti M, Perrelli E, Towe V, Quagliarello V. Role of dipstick testing in the evaluation of urinary infection in nursing home residents. *Infect Control Hosp Epidemiol*. 2007;28(7):889–91.

16. Pecile P, Miorin E, Romanello C, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. *Annals of Internal Medicine*. 2003;138(1):W1–12.

17. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohouc C. High serum procalcitonin concentrations in patients with sepsis and infection. *Lancet*. 1993;341(8844):515–8.

18. Benador N, Siegrist CA, Gendrel D, et al. Procalcitonin is a marker of severity of renal lesions in pyelonephritis. *Pediatrics*. 1998;102(6):1422–5.

19. Gurguez MK, Akarsu S, Yilmaz E, et al. Proinflammatory cytokines and procalcitonin in children with acute pyelonephritis. *Pediatric Nephrology* (Berlin, Germany). 2005;20(10):1445–8.

20. Gervaix A, Galetto-Lacour A, Gueron T, et al. Usefulness of procalcitonin and C-reactive protein rapid tests for the management of children with urinary tract infection. *The Pediatric Infectious Disease Journal*. 2001;20(5):507–11.

21. Smolkin V, Koren A, Raz R, Colodner R, Colodner R, Halevy R. Procalcitonin as a marker of acute pyelonephritis in infants and children. Pediatric Nephrology (Berlin, Germany). 2002;17(6):409–12.

22. Pecile P, Miorin E, Romanello C, et al. Procalcitonin: a marker of severity of acute pyelonephritis among children. *Pediatrics*. 2004;114(2):e249–54.

23. Guven AG, Kazdal HZ, Koyun M, et al. Accurate diagnosis of acute pyelonephritis: How helpful is procalcitonin? *Nuclear Medicine Communications*. 2006;27(9):715–21.

24. Olszyna DP, Vermeulen H, Baan AH, et al. Urine interleukin-8 is a marker for urinary tract infection in postoperative patients. *Infection*. 2001;29(5):274–7.

25. Jantausch BA, O’Donnell R, Wiedermann BL. Urinary interleukin-6 and interleukin-8 in children with urinary tract infection. *Pediatric Nephrology* (Berlin, Germany). 2000;15(3–4):236–40.

26. Sheu JN, Chen MC, Lue KH, et al. Procalcitonin and interleukin-8 in children with urinary tract infection. *Pediatric Nephrology*. 2005;20(10):1445–8.

27. Krzemien G, Roszkowska-Blaim M, Kostro I, et al. Immunological Investigations. 2008;37(7):694–703.

28. Kotoula A, Gardikis S, Tsalkidis A, et al. Procalcitonin for the early prediction of renal parenchymal involvement in children with UTI: preliminary results. *International Urology and Nephrology*. 2009;41(2):393–9.

29. Leroy S, Romanello C, Galetto-Lacour A, et al. Procalcitonin to reduce the number of unnecessary cystographies in children with a urinary tract infection: a European validation study. *The Journal of Pediatrics*. 2007;150(1):89–95.

30. Prat C, Dominguez J, Rodrigo C, et al. Elevated serum procalcitonin values correlate with renal scarring in children with urinary tract infection. *The Pediatric Infectious Disease Journal*. 2003;22(5):438–42.

31. Arao S, Matsuura S, Nonomura M, Miki K, Kabasawa K, Nakanishi H. Procalcitonin as a marker of acute pyelonephritis among children. *Pediatric Nephrology* (Berlin, Germany). 2002;17(6):409–12.

32. Deo SS, Vaidya AK. Elevated levels of secretory immunoglobulin A (sIgA) in urinary tract infections. *Indian Journal of Pediatrics*. 2004;71(1):37–40.

33. Bakakos P, Messaritaki A, Mandyila H, Nicolaidou P, Anagnostakis D. Plasma and urine elastase alpha-1-proteinase inhibitor levels in neonatal urinary tract infection. *Biochemistry of the neonate*. 2002;81(2):109–12.

34. Everaert K, Oostra C, Delanghe J, Vande Walle J, Van Laere M, Oosterlinck W. Diagnosis and localization of a complicated urinary tract infection in neurogenic bladder disease by tubular proteinuria and serum prostate specific antigen. *Spinal Cord*. 1998;36(1):33–8.

35. Smith SD, Wheeler MA, Weiss RM. Detection of urinary tract infections by reduction of nitroblue tetrazolium. *Kidney international*. 1998;54(4):1311–6.

36. Steinhoff J, Eimecke G, Niederstadt C, et al. Renal graft rejection or urinary tract infection? The value of myeloperoxidase, C-reactive protein, and alpha2-macroglobulin in the urine. *Transplantation*. 1997;64(3):443–7.

37. Kotoula A, Gardikis S, Tsalkidis A, et al. Procalcitonin for the early prediction of renal parenchymal involvement in children with UTI: preliminary results. *International Urology and Nephrology*. 2009;41(2):393–9.

38. Leroy S, Romanello C, Galetto-Lacour A, et al. Procalcitonin to reduce the number of unnecessary cystographies in children with a urinary tract infection: a European validation study. *The Journal of Pediatrics*. 2007;150(1):89–95.

39. Prat C, Dominguez J, Rodrigo C, et al. Elevated serum procalcitonin values correlate with renal scarring in children with urinary tract infection. *The Pediatric Infectious Disease Journal*. 2003;22(5):438–42.

40. Roilides E, Papachristou F, Gioulekas E, et al. Increased urine interleukin-6 concentrations correlate with pyelonephritic changes on 99mTc-dimercaptosuccinic acid scans in neonates with urinary tract infections. *The Journal of Infectious Diseases*. 1999;180(3):904–7.

41. Zaki Mel S. Interleukin 8 is a surrogate marker for rapid diagnosis of bacteriuria. *Immunological Investigations*. 2008;37(7):694–703.

42. Oregoni O, Delaunay P, Bruna P, et al. Urinary interleukin-8 is elevated in urinary tract infections independently of the causative germs. *Cytokine*. 2005;31(6):415–8.

43. Rae WH, Evans GS, Finn A. The significance of interleukin 8 in urine. *Archives of Disease in childhood*. 2001;85(3):256–62.

44. Determann RM, Schultz MJ, Geerlings SE. Soluble triggering receptor expressed on myeloid cells-1 is not a sufficient biological marker for infection of the urinary tract. *The Journal of Infectious Diseases*. 2007;195(6):e249–50.